Wholeleaf, a licensed ache therapeutics firm, has drawn bold plan with growth in Bangalore, Mumbai and Hyderabad earlier than penetrating into different key markets in Kolkata, Ahmedabad, Goa and Chennai by finish of this year.
The transfer is a part of the corporate’s plan to have a pan-India presence. It plans to develop its retail footprint to about 7,000 shops by way of tie-ups with mom-and-pop pharmacy shops and huge retail chains akin to Apollo Pharmacy, Wellness Ceaselessly, and Guardian.
Wholeleaf is without doubt one of the fastest-growing early-licensed and compliant entrants in India’s cannabinoid-based therapeutics section.
The corporate’s early investments in compliance, scientific trials and approvals have formed its long-term method as licensed and proof primarily based therapeutics firm.
With a rising portfolio of oral and topical formulations, the corporate addresses a large spectrum of continual ache circumstances, together with migraines, arthritis, fibromyalgia, menstrual ache and neuralgia.
Constructing on this basis, it’s now creating a pipeline of revolutionary options for continual neuropathic ache—an space that continues to pose vital challenges for sufferers and clinicians alike.
Wholeleaf additionally follows a stringent and structured product growth course of involving key stakeholders, together with physicians and pharmacologists. Its formulations are examined by way of third-party, government-certified laboratories to additional guarantee compliance and security requirements.
The proposed growth technique comes at a time when cannabinoid-based therapeutics in India are transitioning from a distinct segment, low-awareness section right into a high-growth rising class, with estimated progress of 20–25 per cent CAGR.
Rising world scientific validation of cannabinoid-based therapies, coupled with the rising prevalence of lifestyle-driven circumstances akin to continual ache, anxiousness, and insomnia, is accelerating demand for such options.
Shivraj Sharma, Founder and CEO, Wholeleaf, expects robust progress within the cannabinoid-based therapeutics trade in India, pushed by the rising burden of continual circumstances and a transparent want for safer, sustainable ache administration options.
“Our growth is targeted on enhancing accessibility by way of trusted retail and medical channels, whereas concurrently strengthening our digital presence to increase attain,” he mentioned.
Printed on Might 23, 2026
Source link
#Wholeleaf #eyes #panIndia #growth #targets #key #markets #year
